Catalyst markets

Program / company	Milestone	Sponsor target	YES / NO	State
DY Z-rostudirsenDYNDyne Therapeutics	FDA decisionDuchenne muscular dystrophy amenable to exon 51 skipping	Jan 21, 202780 days to target	— / —No executable quote	Research
Oral lenacapavirGILDGilead Sciences	FDA decisionHIV pre-exposure prophylaxis	Feb 2, 202792 days to target	— / —No executable quote	Research
BL TinlarebantBLTEBelite Bio	FDA decisionStargardt disease type 1	Feb 12, 2027102 days to target	— / —No executable quote	Research
Zanzalintinib + atezolizumabEXELExelixis	FDA decisionmetastatic colorectal cancer	Mar 3, 2027121 days to target	— / —No executable quote	Research
Lonvo-zNTLAIntellia Therapeutics	FDA decisionhereditary angioedema	Mar 10, 2027128 days to target	— / —No executable quote	Research
UN Oxylanthanum carbonateUNCYUnicycive Therapeutics	FDA decisionhyperphosphatemia in chronic kidney disease patients on dialysis	Mar 25, 2027143 days to target	— / —No executable quote	Research
IN OzekibartINBXInhibrx Biosciences	FDA decisionunresectable or metastatic conventional chondrosarcoma	Apr 14, 2027163 days to target	— / —No executable quote	Research
DeucrictibantPHVSPharvaris	FDA decisionon-demand treatment of hereditary angioedema attacks	Apr 23, 2027172 days to target	— / —No executable quote	Research
AXS-12AXSMAxsome Therapeutics	FDA decisioncataplexy in narcolepsy	May 1, 2027180 days to target	— / —No executable quote	Research
EncaleretBBIOBridgeBio Pharma	FDA decisionautosomal dominant hypocalcemia type 1 (ADH1)	May 8, 2027187 days to target	— / —No executable quote	Research

Sponsor targets are date-only guidance, not trading cutoffs. Research candidates have no executable prices. Forecasts require a dated, sourced model artifact.